184.20EUR+0.11%Mkt Cap: 8.90B $P/E: 83.26Today
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous sys…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap8.90B $
Enterprise Value8.85B $
Revenue (TTM)—
Gross Profit-3.22M $
Net Income (TTM)101.33M $
Revenue/Share—
Last Price184.20 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINBE0003823409
Valuation
P/E (Trailing)83.26
P/E (Forward)—
PEG1.24
EV/EBITDA-2685.49
EV/Revenue—
P/S—
P/B4.12
EPS (TTM)2.22
EPS (Forward)—
52W Range
153.0032% of range250.50
52W High250.50 EUR
52W Low153.00 EUR
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE4.94%
ROA4.82%
Growth
Revenue Growth—
Earnings Growth5.40%
Cash Flow & Leverage
Operating CF-3.30M $
CapEx (TTM)—
FCF Margin—
FCF Yield-0.03%
Net Debt-54.24M $
Net Debt/EBITDA16.46
Balance Sheet
Debt/Equity0.00
Current Ratio141.92
Quick Ratio141.92
Book Value/Sh44.62 EUR
Cash/Share1.121 EUR
Dividends
Fwd Div Rate1.080 EUR
Trail. Div Rate1.080 EUR
Div. Yield0.58%
5Y Avg Yield0.85%
Payout Ratio48.85%
Ex-Div DateMay 7, 2026
Pay Date—
Splits
Last Split2:1
Split DateJun 17, 2005
Analyst Consensus
Rating—
Target (Mean)286.00 EUR
Upside (mean)+55.3%
Target Range286.00 EUR – 286.00 EUR
# Analysts1
Ownership
Shares Out.44.51M
Float20.71M
Insiders53.49%
Institutions8.75%
Technical
SMA 50208.70 (-11.7%)
SMA 200214.35 (-14.1%)
Beta0.39
S&P 52W Chg18.16%
Avg Vol (30d)16.80K
Avg Vol (10d)18.93K
Technical Indicators
RSI (14)33.9
MACD-7.0069
MACD Signal-6.5450
MACD Hist.-0.4619
BB Upper215.04 EUR
BB Middle194.78 EUR
BB Lower174.52 EUR
BB Width20.80%
ATR (14)5.309 EUR
Vol Ratio (20d)0.48x